Table 1.

Systematic reviews of randomized controlled trials involving platelet-rich plasma for knee osteoarthritis. ^*Not a comprehensive list. N refers to the total number of knees that underwent treatment in each study. Age and follow-up are reported as mean, with the “Total” row reported as a weighted mean. BMAC, bone marrow aspirate concentrate; CS, corticosteroid; HA, hyaluronic acid; IKDC, international knee documentation committee; LOE, level of evidence; PLA, placebo; PRP, platelet-rich plasma; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index

Study	LOE	N	Patient Age, years	Follow-Up, months	Outcomes Reported	Outcomes
Belk et al., 2023 [3]	I	1042 PRP, 226 BMAC, 1128 HA	57.7 (PRP), 57.0 (BMAC), 59.0 (HA)	13.5 (PRP), 17.5 (BMAC), 14.4 (HA)	WOMAC, VAS, Subjective IKDC	Higher scores in PRP vs. HA and BMAC vs. HA, no significant differences between PRP and BMAC
Qiao et al., 2023 [4]	I	1046 PRP, 907 HA, 196 PRP + HA, 132 CS, 147 PLA	59.1	6.2	WOMAC, VAS	PRP and PRP + HA had best scores at 3, 6, and 12 months follow-up
Belk et al., 2021 [8]	I	811 PRP, 797 HA	57.6 (PRP), 59.3 (HA)	11.1	WOMAC, VAS, Subjective IKDC	WOMAC scores significantly better in PRP group, VAS scores significantly lower in PRP group, Subjective IKDC scores significantly higher in PRP group
Total	-	2899 PRP, 226 BMAC, 2832 HA, 196 PRP + HA, 132 CS, 147 PLA	58.3	12.5	-	-